-
EP4304561
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4304561
| EP4304561 - PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5- DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-74-CARBOXAMIDE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 15.12.2023 Database last updated on 03.09.2024 | |
| Former | The international publication has been made Status updated on 16.09.2022 | ||
| Former | unknown Status updated on 26.03.2022 | Most recent event Tooltip | 17.05.2024 | Change: Validation states | published on 19.06.2024 [2024/25] | Applicant(s) | For all designated states Bayer Aktiengesellschaft Kaiser-Wilhelm-Allee 1 51373 Leverkusen / DE | [2024/03] | Inventor(s) | 01 /
MERKEL, Susanne 42719 Solingen / DE | 02 /
SERNO, Peter 51467 Bergisch Gladbach / DE | [2024/03] | Representative(s) | BIP Patents c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50 40789 Monheim am Rhein / DE | [2024/03] | Application number, filing date | 22710569.9 | 04.03.2022 | [2024/03] | WO2022EP55519 | Priority number, date | EP20210161493 | 09.03.2021 Original published format: EP 21161493 | [2024/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022189278 | Date: | 15.09.2022 | Language: | EN | [2022/37] | Type: | A1 Application with search report | No.: | EP4304561 | Date: | 17.01.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.09.2022 takes the place of the publication of the European patent application. | [2024/03] | Search report(s) | International search report - published on: | EP | 15.09.2022 | Classification | IPC: | A61K9/16, A61K9/20 | [2024/03] | CPC: |
A61K9/1635 (EP,IL,KR);
A61K9/2027 (EP,IL,KR,US);
A61K31/4439 (KR,US);
A61K9/0053 (US);
A61P27/02 (KR);
A61P7/10 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/03] | Extension states | BA | 09.10.2023 | ME | 09.10.2023 | Validation states | MA | 09.10.2023 | TN | 09.10.2023 | Title | German: | PHARMAZEUTISCHE DOSIERFORMEN MIT (4S)-24-CHLOR-4-ETHYL-73-FLUOR-35-METHOXY-32,5-DIOXO-14-(TRIFLUORMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3!TRIAZOLA-2(1,7(1)-DIBENZENHEPTAPHAN | [2024/03] | English: | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5- DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | [2024/03] | French: | FORMES POSOLOGIQUES PHARMACEUTIQUES COMPRENANT DU (4S)-24-CHLORO-4-ÉTHYL-73-FLUORO-35-MÉTHOXY-32,5-DIOXO-14-(TRIFLUOROMÉTHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZÉNAHEPTAPHANE-74-CARBOXAMIDE | [2024/03] | Entry into regional phase | 09.10.2023 | National basic fee paid | 09.10.2023 | Designation fee(s) paid | 09.10.2023 | Examination fee paid | Examination procedure | 09.10.2023 | Examination requested [2024/03] | 09.10.2023 | Date on which the examining division has become responsible | 12.04.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 26.02.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [YD]WO2017005725 (BAYER PHARMA AG [DE]); | [YD]WO2020210629 (BRISTOL MYERS SQUIBB CO [US]) | by applicant | WO2016168098 | WO2017005725 | WO2019175043 | WO2020127504 | WO2020210629 |